FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4286298889> ?p ?o ?g. }

• W4286298889 endingPage "4019" @default.
• W4286298889 startingPage "4019" @default.
• W4286298889 abstract "4019 Background: Adjuvant CAP is the standard of care for resected CCA according to the BILCAP trial. However, the prognosis of patients with resected CCA is still poor. As GemCis is the standard first-line therapy for unresectable/metastatic BTC, we investigated the role of adjuvant GemCis in resected BTC. Because BTC is heterogeneous disease according to the primary tumor site, this study included only pts with resected LN+ extrahepatic CCA. Methods: STAMP is a multicenter, open-label, randomized phase 2 study. Pts with ≥ 19 years, ECOG PS 0/1, adenocarcinoma of perihilar or distal bile duct, at least one regional LN metastasis (N1 or greater), complete macroscopic (R0 or R1) resection within 12 weeks before randomization were eligible. Distant metastasis or R2 disease, previous chemotherapy or radiotherapy, or a serum CA 19-9 level ≥ 100 U/mL were ineligible. Pts were randomized 1:1 to GemCis (Gem 1,000 mg/m2 IV, and Cis 25 mg/m2 IV on day 1 and 8, every 3 weeks) or CAP (1,250 mg/m2 orally twice daily on days 1-14, every 3 weeks) for 8 cycles. Tumor response was performed every 12 weeks for the first 2 years, followed by every 24 weeks for the next 3 years. Primary endpoint was disease-free survival (DFS). Secondary endpoints were overall survival (OS) and safety. This study was designed to improved 2-year DFS rates from 22% (CAP) to 40% (GemCis). Considering follow-up loss rates of 10% with a 1-sided type I error of 0.1 and a type II error of 0.2, a total of 100 patients (50 in each arm) were required. Results: Between JUL 2017 and NOV 2020, a total of 101 pts (50 for GemCis group and 51 for CAP group) were included in the ITT population. Perihilar and distal bile duct were primary tumor sites in 45 pts (44.6%) and 56 pts (55.4%), respectively and 32 pts (31.7%) had R1 resection. Pts characteristics were well balanced between two arms. With median follow-up duration of 28.7 mo (IQR 17.2-39.4), the 2-year DFS rates were 38.5% (1-sided 90% CI, 29.5-47.4%) in GemCis group and 25.1% (17.4-33.5%) in CAP group. The median DFS were 14.3 mo (10.7-16.5 mo) in GemCis group and 11.1 mo (8.4-12.7 mo) in CAP group (HR=0.96 [0.71-1.30], p=0.86). The median OS were 35.7 mo (29.5 mo-not estimated [NE]) in GemCis group and 35.7 mo (30.9 mo-NE) in CAP group (HR=1.08 [0.72-1.64], p=0.81). Grade 3-4 adverse events (AEs) occurred in 42 pts (84.0%) and 8 (16.0%) in GemCis and CAP groups, respectively. The most common AE of grade 3-4 was neutropenia (n = 36, 72.0%) in GemCis group and hand-foot skin reaction (n = 4, 8.0%) in CAP group. Conclusions: In this study including prognostically homogeneous pts population, GemCis was feasible as adjuvant therapy, but failed to improve survival outcomes compared to CAP. CAP should remain standard adjuvant therapy for resected BTC. Clinical trial information: NCT03079427." @default.
• W4286298889 created "2022-07-21" @default.
• W4286298889 creator A5004673227 @default.
• W4286298889 creator A5017077151 @default.
• W4286298889 creator A5023344582 @default.
• W4286298889 creator A5035547791 @default.
• W4286298889 creator A5037596654 @default.
• W4286298889 creator A5044558998 @default.
• W4286298889 creator A5045935665 @default.
• W4286298889 creator A5046517508 @default.
• W4286298889 creator A5050625196 @default.
• W4286298889 creator A5064407466 @default.
• W4286298889 creator A5065909568 @default.
• W4286298889 creator A5066759908 @default.
• W4286298889 creator A5090754319 @default.
• W4286298889 date "2022-06-01" @default.
• W4286298889 modified "2023-10-16" @default.
• W4286298889 title "Adjuvant gemcitabine plus cisplatin (GemCis) versus capecitabine (CAP) in patients (pts) with resected lymph node (LN)-positive extrahepatic cholangiocarcinoma (CCA): A multicenter, open-label, randomized, phase 2 study (STAMP)." @default.
• W4286298889 doi "https://doi.org/10.1200/jco.2022.40.16_suppl.4019" @default.
• W4286298889 hasPublicationYear "2022" @default.
• W4286298889 type Work @default.
• W4286298889 citedByCount "8" @default.
• W4286298889 countsByYear W42862988892023 @default.
• W4286298889 crossrefType "journal-article" @default.
• W4286298889 hasAuthorship W4286298889A5004673227 @default.
• W4286298889 hasAuthorship W4286298889A5017077151 @default.
• W4286298889 hasAuthorship W4286298889A5023344582 @default.
• W4286298889 hasAuthorship W4286298889A5035547791 @default.
• W4286298889 hasAuthorship W4286298889A5037596654 @default.
• W4286298889 hasAuthorship W4286298889A5044558998 @default.
• W4286298889 hasAuthorship W4286298889A5045935665 @default.
• W4286298889 hasAuthorship W4286298889A5046517508 @default.
• W4286298889 hasAuthorship W4286298889A5050625196 @default.
• W4286298889 hasAuthorship W4286298889A5064407466 @default.
• W4286298889 hasAuthorship W4286298889A5065909568 @default.
• W4286298889 hasAuthorship W4286298889A5066759908 @default.
• W4286298889 hasAuthorship W4286298889A5090754319 @default.
• W4286298889 hasConcept C121608353 @default.
• W4286298889 hasConcept C126322002 @default.
• W4286298889 hasConcept C126894567 @default.
• W4286298889 hasConcept C141071460 @default.
• W4286298889 hasConcept C143998085 @default.
• W4286298889 hasConcept C168563851 @default.
• W4286298889 hasConcept C203092338 @default.
• W4286298889 hasConcept C204243189 @default.
• W4286298889 hasConcept C2776694085 @default.
• W4286298889 hasConcept C2777909004 @default.
• W4286298889 hasConcept C2780258809 @default.
• W4286298889 hasConcept C509974204 @default.
• W4286298889 hasConcept C526805850 @default.
• W4286298889 hasConcept C71924100 @default.
• W4286298889 hasConcept C90924648 @default.
• W4286298889 hasConceptScore W4286298889C121608353 @default.
• W4286298889 hasConceptScore W4286298889C126322002 @default.
• W4286298889 hasConceptScore W4286298889C126894567 @default.
• W4286298889 hasConceptScore W4286298889C141071460 @default.
• W4286298889 hasConceptScore W4286298889C143998085 @default.
• W4286298889 hasConceptScore W4286298889C168563851 @default.
• W4286298889 hasConceptScore W4286298889C203092338 @default.
• W4286298889 hasConceptScore W4286298889C204243189 @default.
• W4286298889 hasConceptScore W4286298889C2776694085 @default.
• W4286298889 hasConceptScore W4286298889C2777909004 @default.
• W4286298889 hasConceptScore W4286298889C2780258809 @default.
• W4286298889 hasConceptScore W4286298889C509974204 @default.
• W4286298889 hasConceptScore W4286298889C526805850 @default.
• W4286298889 hasConceptScore W4286298889C71924100 @default.
• W4286298889 hasConceptScore W4286298889C90924648 @default.
• W4286298889 hasIssue "16_suppl" @default.
• W4286298889 hasLocation W42862988891 @default.
• W4286298889 hasOpenAccess W4286298889 @default.
• W4286298889 hasPrimaryLocation W42862988891 @default.
• W4286298889 hasRelatedWork W2139955290 @default.
• W4286298889 hasRelatedWork W2382613782 @default.
• W4286298889 hasRelatedWork W2391084975 @default.
• W4286298889 hasRelatedWork W2419408601 @default.
• W4286298889 hasRelatedWork W2900510703 @default.
• W4286298889 hasRelatedWork W3007914843 @default.
• W4286298889 hasRelatedWork W3031015708 @default.
• W4286298889 hasRelatedWork W4386216180 @default.
• W4286298889 hasRelatedWork W4386225391 @default.
• W4286298889 hasRelatedWork W4386225412 @default.
• W4286298889 hasVolume "40" @default.
• W4286298889 isParatext "false" @default.
• W4286298889 isRetracted "false" @default.
• W4286298889 workType "article" @default.